+91 789 2456 581 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
24 Oct 2017

US FDA approval of Stryker’s cementless Mako Total Knee with Triathlon Tritanium

Stryker’s Joint Replacement division has announced that its cementless Mako Total Knee with Triathlon Tritanium has received 510(k) market clearance by the US Food and Drug Administration.

Triathlon Tritanium combines the kinematics of Stryker’s market leading Triathlon knee implant with the latest in highly porous biologic fixation technology for a knee system like no other. The innovation of Tritanium’s tibial baseplate and metal-backed patella components are enabled by Stryker’s proprietary AMagine additive manufacturing technology and are SOMA-designed.

With cementless procedures rising in popularity and becoming a fast-growing trend1, Mako Total Knee with Triathlon Tritanium expands the current robotics offering to provide a cementless solution for orthopaedic surgeons seeking a more predictable surgical experience combined with increased operating room efficiency, biologic fixation and an alternative to bone cement.

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.